ES2563677T3 - Composiciones de combinaciones de Neisseria - Google Patents

Composiciones de combinaciones de Neisseria Download PDF

Info

Publication number
ES2563677T3
ES2563677T3 ES10179061.6T ES10179061T ES2563677T3 ES 2563677 T3 ES2563677 T3 ES 2563677T3 ES 10179061 T ES10179061 T ES 10179061T ES 2563677 T3 ES2563677 T3 ES 2563677T3
Authority
ES
Spain
Prior art keywords
seq
sequence
amino acid
pairs
protein comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES10179061.6T
Other languages
English (en)
Inventor
Marzia Monica Giuliani
Mariagrazia Pizza
Rino Rappuoli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9911692.3A external-priority patent/GB9911692D0/en
Priority claimed from GBGB9919705.5A external-priority patent/GB9919705D0/en
Priority claimed from GB0005730A external-priority patent/GB0005730D0/en
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Application granted granted Critical
Publication of ES2563677T3 publication Critical patent/ES2563677T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Abstract

Una composición que comprende dos o más proteínas de Neisseria diferentes, en la que las dos o más proteínas de Neisseria diferentes incluyen una primera proteína de una bacteria de Neisseria y una segunda proteína de una bacteria de Neisseria, y en la que (i) la primera proteína comprende una secuencia de aminoácidos seleccionada de (a) SEC ID Nº: 3898; y (b) una secuencia que tiene una identidad de secuencia mayor del 80 % con la SEC ID Nº: 3898; y la segunda proteína comprende una secuencia de aminoácidos seleccionada de (a) una de las SEC ID Nº pares seleccionadas de las SEC ID Nº: 2182 a 2186; y (b) una secuencia que tiene una identidad de secuencia mayor del 80 % con una de las SEC ID Nº: 2182 a 2186 pares; o (ii) la primera proteína comprende una secuencia de aminoácidos seleccionada de (a) SEC ID Nº: 3900; y (b) una secuencia que tiene una identidad de secuencia mayor del 80 % con la SEC ID Nº: 3900; y la segunda proteína comprende una secuencia de aminoácidos seleccionada de (a) una de las SEC ID Nº pares seleccionadas de las SEC ID Nº: 2182 a 2186; y (b) una secuencia que tiene una identidad de secuencia mayor del 80 % con una de las SEC ID Nº: 2182 a 2186 pares; o (iii) la primera proteína comprende una secuencia de aminoácidos seleccionada de (a) SEC ID Nº: 3902; y (b) una secuencia que tiene una identidad de secuencia mayor del 80 % con la SEC ID Nº: 3902; y la segunda proteína comprende una secuencia de aminoácidos seleccionada de (a) una de las SEC ID Nº pares seleccionadas de las SEC ID Nº: 2182 a 2186; y (b) una secuencia que tiene una identidad de secuencia mayor del 80 % con una de las SEC ID Nº: 2182 a 2186 pares.

Description

imagen1
imagen2
imagen3
imagen4
imagen5

Claims (1)

  1. imagen1
ES10179061.6T 1999-05-19 2000-05-19 Composiciones de combinaciones de Neisseria Expired - Lifetime ES2563677T3 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9911692 1999-05-19
GBGB9911692.3A GB9911692D0 (en) 1999-05-19 1999-05-19 Antigenic combinations
GBGB9919705.5A GB9919705D0 (en) 1999-08-19 1999-08-19 Antigenic combinations
GB9919705 1999-08-19
GB0005730A GB0005730D0 (en) 2000-03-09 2000-03-09 Antigenic combinations
GB0005730 2000-03-09

Publications (1)

Publication Number Publication Date
ES2563677T3 true ES2563677T3 (es) 2016-03-15

Family

ID=27255587

Family Applications (2)

Application Number Title Priority Date Filing Date
ES10179061.6T Expired - Lifetime ES2563677T3 (es) 1999-05-19 2000-05-19 Composiciones de combinaciones de Neisseria
ES10178238.1T Expired - Lifetime ES2563650T3 (es) 1999-05-19 2000-05-19 Composiciones de combinaciones de Neisseria

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES10178238.1T Expired - Lifetime ES2563650T3 (es) 1999-05-19 2000-05-19 Composiciones de combinaciones de Neisseria

Country Status (14)

Country Link
US (9) US7862827B2 (es)
EP (6) EP2270173B1 (es)
JP (3) JP5622344B2 (es)
CN (2) CN100338218C (es)
AU (3) AU783894B2 (es)
BR (1) BR0010721A (es)
CA (3) CA2929348A1 (es)
CY (2) CY1117235T1 (es)
DK (2) DK2270173T3 (es)
ES (2) ES2563677T3 (es)
MX (1) MXPA01011867A (es)
NZ (4) NZ536676A (es)
PT (2) PT2270173E (es)
WO (1) WO2000071725A2 (es)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2266656A1 (en) 1996-09-17 1998-03-26 Chiron Corporation Compositions and methods for treating intracellular diseases
EP2261347A3 (en) 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
US10967045B2 (en) * 1998-11-02 2021-04-06 Secretary of State for Health and Social Care Multicomponent meningococcal vaccine
GB9823978D0 (en) * 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
CA2372235A1 (en) 1999-04-30 2000-11-09 Rino Rappuoli Conserved neisserial antigens
AU783894B2 (en) 1999-05-19 2005-12-22 Novartis Vaccines And Diagnostics S.R.L. Combination neisserial compositions
GB9916529D0 (en) * 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
EP1226253A2 (en) 1999-10-29 2002-07-31 Chiron S.P.A. Neisserial antigenic peptides
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
DK1947187T5 (da) 2000-02-28 2011-10-24 Novartis Vaccines & Diagnostic Hybrid ekspression af neisserial-proteiner
AU2004203417B2 (en) * 2000-05-08 2008-02-14 Microscience Limited Virulence genes, proteins, and their use
GB0012079D0 (en) * 2000-05-18 2000-07-12 Microscience Ltd Virulence gene and protein, and their use
GB0020952D0 (en) * 2000-08-24 2000-10-11 Microscience Ltd Genes and proteins and their uses
PT2332581E (pt) 2001-01-23 2015-10-16 Sanofi Pasteur Inc Vacina meningocócica tri- ou tetravalente de conjugados de polissacárido e crm-197
US7261901B2 (en) 2001-01-31 2007-08-28 University Of Iowa Research Foundation Vaccine and compositions for the prevention and treatment of neisserial infections
US7250172B2 (en) 2001-01-31 2007-07-31 University Of Iowa Research Foundation Vaccine and compositions for the prevention and treatment of neisserial infections
GB0108024D0 (en) 2001-03-30 2001-05-23 Chiron Spa Bacterial toxins
GB0114940D0 (en) * 2001-06-19 2001-08-08 Chiron Spa Gene expression during meningococcus adhesion
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
ATE469915T1 (de) 2001-07-27 2010-06-15 Novartis Vaccines & Diagnostic Antikörper gegen das meningokokken adhäsin app
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AU2012202488B2 (en) * 2001-09-06 2014-01-16 Glaxosmithkline Biologicals S.A. Hybrid and tandem expression of Neisserial proteins
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
CA2493124C (en) * 2002-08-02 2014-04-29 Glaxosmithkline Biologicals S.A. Vaccine
GB0220197D0 (en) * 2002-08-30 2002-10-09 Univ Utrecht Refolding method
BR0313100A (pt) * 2002-08-02 2005-06-21 Glaxosmithkline Biolog Sa Composição imunogênica, composição imunogênica isolada, vacina, método de tratamento ou prevenção de doença bacteriana gram-negativa, uso da vacina, cepa bacteriana gram-negativa geneticamente manipulada, método para preparar a composição imunogênica, método para preparar a vacina, método de preparar uma imunoglobulina para uso na prevenção ou tratamento de infecção neisserial, preparação de imunoglobulina, preparação farmacêutica, e, uso da preparação farmacêutica
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
CN1809380B (zh) 2002-10-11 2010-05-12 启龙有限公司 广泛防御高毒性脑膜炎球菌谱系的多肽-疫苗
WO2004046177A2 (en) * 2002-11-15 2004-06-03 Chiron Srl Unexpected surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
GB0315021D0 (en) * 2003-06-26 2003-07-30 Chiron Srl Immunogenic gonococcal compositions
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0419408D0 (en) * 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
EP1856291A4 (en) * 2005-03-04 2009-04-01 Verenium Corp NUCLEIC ACIDS AND PROTEINS, AND METHODS OF MAKING AND USING SAME
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
KR20080090447A (ko) * 2005-12-23 2008-10-08 임페리얼 이노베이션스 리미티드 수막구균 백신 및 그의 용도
CU23572A1 (es) * 2006-03-31 2010-09-30 Ct Ingenieria Genetica Biotech Composición farmacéutica que comprende la proteína nmb0938
CU23575A1 (es) * 2006-03-31 2010-09-30 Ct Ingenieria Genetica Biotech Composición farmacéutica que comprende la proteína nmb0606
CN101479293A (zh) * 2006-06-29 2009-07-08 诺华有限公司 脑膜炎奈瑟球菌多肽
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
EP2886551A3 (en) * 2008-02-21 2015-09-23 Novartis AG Meningococcal fhbp polypeptides
GB0810742D0 (en) * 2008-06-12 2008-07-16 Univ Nottingham Enzyme
WO2010028246A2 (en) * 2008-09-05 2010-03-11 Id Biomedical Corporation Of Quebec Novel compositions and adjuvants
GB0816447D0 (en) * 2008-09-08 2008-10-15 Glaxosmithkline Biolog Sa Vaccine
IT1394288B1 (it) * 2008-09-12 2012-06-06 Novartis Vaccines & Diagnostic Immunogeni di proteine che legano il fattore h.
PL2411048T3 (pl) 2009-03-24 2020-11-16 Glaxosmithkline Biologicals Sa Adjuwantowe meningokokowe białko wiążące czynnik h
EP2544714A1 (en) 2010-03-10 2013-01-16 GlaxoSmithKline Biologicals S.A. Vaccine composition
BR112012022800A2 (pt) * 2010-03-11 2018-05-15 Glaxosmithkline Biologicals Sa composição imunogênica ou vacina, cepa bacteriana gram-negativa geneticamente engenheirada, métodos para o tratamento ou prevenção de infecção ou doença, para produzir uma composição imunogênica ou uma vacina, e para preparar uma imunoglobulina, preparação da imunoglobulina, e, preparação farmacêutica
CA2803239A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
AU2011284809B2 (en) * 2010-07-30 2015-04-02 Griffith University Recombinant Neisseria meningitidis Por A porin proteins.
RU2580620C2 (ru) 2010-08-23 2016-04-10 ВАЙЕТ ЭлЭлСи СТАБИЛЬНЫЕ КОМПОЗИЦИИ АНТИГЕНОВ Neisseria meningitidis rLP2086
GB201014967D0 (en) * 2010-09-09 2010-10-20 Univ Southampton Composition
BR112013005626B1 (pt) 2010-09-10 2022-07-26 Glaxosmithkline Biologicals Sa Meningococo, processo para a preparação de uma cepa meningocócica, vesículas de membrana externa, composição farmacêutica imunogênica, e, uso de uma composição
GB201015132D0 (en) * 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
WO2012032489A1 (en) 2010-09-10 2012-03-15 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
EP2635593B1 (en) * 2010-11-05 2016-09-14 Institut National de la Sante et de la Recherche Medicale (INSERM) Vaccines for preventing meningococcal infections
GB201102090D0 (en) * 2011-02-08 2011-03-23 Univ Sheffield Antigenic polypeptide
GB201120634D0 (en) * 2011-11-30 2012-01-11 Univ Sheffield Adjuvant polypeptide
MX2014008988A (es) * 2012-02-02 2014-08-27 Novartis Ag Promotores para aumento de expresion de proteinas en meningococo.
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
MX357538B (es) 2012-06-14 2018-07-13 Novartis Ag Vacunas para meningococo de serogrupo x.
GB201211154D0 (en) * 2012-06-22 2012-08-08 Univ Southampton Composition
HK1205138A1 (en) 2012-07-27 2015-12-11 Institut National De La Santé Et De La Recherche Médicale (Inserm) Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
US9725701B2 (en) 2013-03-15 2017-08-08 Iowa Corn Promotion Board Prokarytoic-type isocitrate dehydrogenase and its application for improving nitrogen utilization in transgenic plants
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
EP3229835A1 (en) 2014-12-09 2017-10-18 Sanofi Pasteur Compositions comprising n. meningitidis proteins
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
RS65362B1 (sr) 2016-09-02 2024-04-30 Sanofi Pasteur Inc Vakcina protiv neisseria meningitidis
US10183070B2 (en) 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US20220081707A1 (en) * 2018-07-25 2022-03-17 The Trustees Of Indiana University Diagnostic assay for a strain of neisseria meningitidis
EP4034157A1 (en) 2019-09-27 2022-08-03 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US11618902B2 (en) * 2020-03-30 2023-04-04 Jiangnan University Bacillus subtilis for producing N-acetylneuraminic acid and application thereof
CN111394410B (zh) * 2020-03-30 2022-02-01 江南大学 一种高催化活性神经氨酸合酶及应用
US11579093B2 (en) 2020-04-22 2023-02-14 SciLogica Corp. Optical component
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
US20240424079A1 (en) * 2021-07-05 2024-12-26 Evaxion Biotech A/S Vaccines targeting Neisseria gonorrhoeae
US20250043259A1 (en) * 2021-11-11 2025-02-06 Institut National De La Recherche Scientifique Endonucleases that selectively cleave single-stranded nucleic acids and uses thereof
CN119685283B (zh) * 2025-01-09 2025-10-14 武汉茵智生物技术有限公司 一种n-乙酰神经氨酸合酶突变体及其在n-乙酰神经氨酸生产中的应用

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
US4239749A (en) * 1979-09-27 1980-12-16 United States Of America Neisseria gonorrhoeae vaccine
EP0273116A3 (en) 1986-10-09 1990-05-02 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Gonococcal and meningococcal polypeptides, vaccines and diagnostics
JPH01125328A (ja) 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
NL8803111A (nl) * 1988-12-19 1990-07-16 Nederlanden Staat Multivalent meningococcen klasse i buitenmembraaneiwit vaccin.
EP0467714A1 (en) 1990-07-19 1992-01-22 Merck & Co. Inc. The class II protein of the outer membrane of neisseria meningitidis
CA2105382C (en) 1991-03-14 1999-01-19 Neil Goldstein Recombinant hybrid porin epitopes
FR2692592B1 (fr) 1992-06-19 1995-03-31 Pasteur Merieux Serums Vacc Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant.
DE69423383T2 (de) 1993-05-13 2000-08-24 American Cyanamid Co., Wayne Herstellung und Verwendungen von LOS-verminderten Aussenmembran-Proteinen von Gram-negativen Kokken
US5439808A (en) 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
DK0710118T3 (da) 1994-04-20 1999-08-09 Us Army Vaccine mod infektioner med gram-negative bakterier
FR2720408B1 (fr) 1994-05-31 1996-08-14 Pasteur Merieux Serums Vacc Fragments Tbp2 de Neisseria meningitidis.
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
EP0854729B2 (en) * 1995-09-18 2008-10-22 United States Army Medical Research Materiel Command (USAMRMC) Improved methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines
FR2739624B1 (fr) 1995-10-10 1997-12-05 Pasteur Merieux Serums Vacc Nouvelle sous-unite tbp2 de neisseria meningitidis
PL328096A1 (en) 1996-02-01 1999-01-04 North American Vaccine Expression of external membrane (mb3) protein of neisseria meningitidis of b group in yeasts and vaccines
US6472518B1 (en) 1996-10-24 2002-10-29 Centers For Disease Control And Prevention, As Represented By The Secretary, Department Of Health And Human Services Invasion associated genes from Neisseria meningitidis serogroup B
CA2271720A1 (en) 1996-10-31 1998-05-07 Human Genome Sciences, Inc. Streptococcus pneumoniae polynucleotides and sequences
CA2297072A1 (en) 1997-07-17 1999-01-28 Baxter Healthcare S.A. Immunogenic conjugates comprising a group b meningococcal porin and an h. influenzae polysaccharide
BR9811907A (pt) * 1997-08-15 2000-08-15 Univ Utrecht Proteìna de ligação de lactoferrina de neisseria
EP1900818A3 (en) * 1997-11-06 2008-06-11 Novartis Vaccines and Diagnostics S.r.l. Neisserial antigens
US6914131B1 (en) 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
GB9726398D0 (en) * 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
WO1999036544A2 (en) 1998-01-14 1999-07-22 Chiron S.P.A. Neisseria meningitidis antigens
GB9808866D0 (en) 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
US20070026021A1 (en) 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
EP2261347A3 (en) 1998-05-01 2012-01-11 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
AT2941U1 (de) 1998-05-06 1999-07-26 Fleischhacker Gerhard Flexible flüssigkeitssperre
JP5074644B2 (ja) 1998-05-29 2012-11-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 組合わせの髄膜炎菌ｂ／ｃワクチン
EP1741443B1 (en) 1998-05-29 2014-05-21 Novartis Vaccines and Diagnostics, Inc. Combination meningitidis B/C vaccines
US6248329B1 (en) 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
MXPA01003557A (es) * 1998-10-09 2004-04-05 Chiron Corp Secuencias genomicas de neisseria y metodos para su uso.
GB9823978D0 (en) * 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
US20030215469A1 (en) 1998-11-02 2003-11-20 Microbiological Research Authority Multicomponent meningococcal vaccine
JP4812942B2 (ja) * 1999-02-26 2011-11-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル ＣＧモチーフを含むオリゴヌクレオチドを用いるＮｅｉｓｓｅｒｉａ抗原殺菌活性の増強
CA2371032A1 (en) 1999-04-30 2000-11-09 Chiron Corporation Neisseria genomic sequences and methods of their use
CA2372235A1 (en) * 1999-04-30 2000-11-09 Rino Rappuoli Conserved neisserial antigens
AU783894B2 (en) * 1999-05-19 2005-12-22 Novartis Vaccines And Diagnostics S.R.L. Combination neisserial compositions
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
EP1226253A2 (en) 1999-10-29 2002-07-31 Chiron S.P.A. Neisserial antigenic peptides
AU1917501A (en) 1999-11-12 2001-06-06 University Of Iowa Research Foundation, The Control of neisserial membrane synthesis
CA2871789C (en) 2000-01-17 2017-04-04 Novartis Vaccines And Diagnostics S.R.L. Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
MXPA02007184A (es) 2000-01-25 2004-02-26 Univ Queensland Proteinas que comprenden regiones conservadas de antigenos de superficie nhha de neisseria meningitidis.
DK1947187T5 (da) 2000-02-28 2011-10-24 Novartis Vaccines & Diagnostic Hybrid ekspression af neisserial-proteiner
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
KR20030024811A (ko) 2000-07-27 2003-03-26 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 나이세리아 메닌지티디스에 의하여 유발되는 질병에 대한광범위하게 유효한 보호를 위한 백신
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0103424D0 (en) * 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
CN1306956C (zh) 2001-04-17 2007-03-28 希龙公司 诱导功能活性抗体的脑膜炎球菌b抗原表位的分子模拟物
EP1409013B1 (en) 2001-07-26 2009-11-18 Novartis Vaccines and Diagnostics S.r.l. Vaccines comprising aluminium adjuvants and histidine
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
ATE469915T1 (de) 2001-07-27 2010-06-15 Novartis Vaccines & Diagnostic Antikörper gegen das meningokokken adhäsin app
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0130123D0 (en) 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
CA2493124C (en) 2002-08-02 2014-04-29 Glaxosmithkline Biologicals S.A. Vaccine
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
CN1809380B (zh) 2002-10-11 2010-05-12 启龙有限公司 广泛防御高毒性脑膜炎球菌谱系的多肽-疫苗
WO2004046177A2 (en) 2002-11-15 2004-06-03 Chiron Srl Unexpected surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
WO2004054611A1 (en) 2002-12-16 2004-07-01 Nasjonalt Folkehelseinstitutt Meningococcal vaccine based on outer membrane proteins porb2 and pora
EP1590459A2 (en) 2003-01-15 2005-11-02 Wyeth Holdings Corporation Methods for increasing neisseria protein expression and compositions thereof
ES2461350T3 (es) 2003-01-30 2014-05-19 Novartis Ag Vacunas inyectables contra múltiples serogrupos de meningococos
BRPI0409459A (pt) 2003-04-16 2006-05-02 Wyeth Corp novas composições imunogênicas para a prevenção e tratamento de doença meningocócica
GB0315021D0 (en) 2003-06-26 2003-07-30 Chiron Srl Immunogenic gonococcal compositions
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
NZ546430A (en) 2003-10-02 2009-04-30 Novartis Vaccines & Diagnostic Liquid vaccines for multiple meningococcal serogroups
JP5173194B2 (ja) 2003-12-23 2013-03-27 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0409748D0 (en) 2004-04-30 2004-06-09 Chiron Srl Lactoferrin cleavage
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
LT2682126T (lt) 2005-01-27 2017-02-27 Children`s Hospital & Research Center at Oakland Gna1870 pagrindu gaminamos pūslelių pavidalo vakcinos, skirtos plataus spektro apsaugai nuo neisseria meningitidis sukeltų ligų
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
WO2008001244A2 (en) 2006-06-23 2008-01-03 Harun Aksoy A stone
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
WO2008125985A2 (en) 2007-04-11 2008-10-23 Novartis Ag Blocking interaction between pathogen factors and factor h to inhibit hemorrhagic syndromes
JP5637848B2 (ja) 2007-06-04 2014-12-10 ノバルティス アーゲー 髄膜炎ワクチンの製剤化
EP2185576A4 (en) 2007-08-02 2011-01-12 Childrens Hosp & Res Ct Oak FHBP- AND LPXL1-BASED VESICIUM VACCINES FOR BROADBAND PROTECTION AGAINST NEISSERIA MENINGITIDIS-RELATED DISEASES
EP2886551A3 (en) 2008-02-21 2015-09-23 Novartis AG Meningococcal fhbp polypeptides
EP2631245A1 (en) 2008-03-10 2013-08-28 Children's Hospital & Research Center at Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
RU2477145C2 (ru) 2008-05-30 2013-03-10 ДЗЕ Ю.Эс.Эй., ЭС РЕПРЕЗЕНТЕД БАЙ ДЗЕ СЕКРЕТАРИ ОФ ДЗЕ АРМИ, ОН БЕХАФ ОФ УОЛТЕР РИД АРМИ Мультивалентная вакцина из нативных везикул наружной мембраны менингококков, способы ее получения и применения
CA2733943A1 (en) 2008-09-03 2010-03-11 Children's Hospital & Research Center At Oakland Peptides presenting an epitope of an a domain of factor h binding protein and methods of use
GB0816284D0 (en) 2008-09-05 2008-10-15 Nat Biolog Standards Board Vaccine
IT1394288B1 (it) 2008-09-12 2012-06-06 Novartis Vaccines & Diagnostic Immunogeni di proteine che legano il fattore h.
GB0819633D0 (en) 2008-10-25 2008-12-03 Isis Innovation Composition
AU2010227221B2 (en) 2009-03-24 2015-01-22 Novartis Ag Combinations including pneumococcal serotype 14 saccharide
PL2411048T3 (pl) 2009-03-24 2020-11-16 Glaxosmithkline Biologicals Sa Adjuwantowe meningokokowe białko wiążące czynnik h
EP2544714A1 (en) 2010-03-10 2013-01-16 GlaxoSmithKline Biologicals S.A. Vaccine composition
WO2011126863A1 (en) 2010-03-30 2011-10-13 Children's Hospital & Research Center Oakland Factor h binding proteins (fhbp) with altered properties and methods of use thereof
WO2013177397A1 (en) 2012-05-24 2013-11-28 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Multivalent meningococcal conjugates and methods for preparing cojugates

Also Published As

Publication number Publication date
CA2929348A1 (en) 2000-11-30
EP2270174A1 (en) 2011-01-05
CA2373236C (en) 2014-08-26
CN102580072A (zh) 2012-07-18
NZ528254A (en) 2005-07-29
AU2009200865A1 (en) 2009-03-26
AU2006201153A1 (en) 2006-04-13
EP2270173A1 (en) 2011-01-05
EP2258851A1 (en) 2010-12-08
EP1860191A3 (en) 2008-02-13
MXPA01011867A (es) 2002-05-06
JP2007224047A (ja) 2007-09-06
WO2000071725A3 (en) 2001-06-28
US20160175422A1 (en) 2016-06-23
US20070231342A1 (en) 2007-10-04
AU5097700A (en) 2000-12-12
US20050244436A1 (en) 2005-11-03
CN100338218C (zh) 2007-09-19
EP2270173B1 (en) 2016-01-06
WO2000071725A2 (en) 2000-11-30
PT2270172E (pt) 2016-03-31
US9364528B1 (en) 2016-06-14
NZ515935A (en) 2004-01-30
US20170165346A1 (en) 2017-06-15
CA2838395A1 (en) 2000-11-30
JP5622344B2 (ja) 2014-11-12
US20160151476A1 (en) 2016-06-02
US9610342B2 (en) 2017-04-04
CN1362992A (zh) 2002-08-07
EP1179072A2 (en) 2002-02-13
EP2270172B1 (en) 2016-01-13
EP1860191A2 (en) 2007-11-28
US20140037668A1 (en) 2014-02-06
DK2270173T3 (en) 2016-03-07
US20150174231A1 (en) 2015-06-25
PT2270173E (pt) 2016-03-28
CY1117235T1 (el) 2017-04-05
JP2013047274A (ja) 2013-03-07
AU783894B2 (en) 2005-12-22
US20120135026A1 (en) 2012-05-31
DK2270172T3 (en) 2016-02-29
ES2563650T3 (es) 2016-03-15
NZ545647A (en) 2008-02-29
AU2009200865B2 (en) 2012-11-08
JP2003500420A (ja) 2003-01-07
US7862827B2 (en) 2011-01-04
US20110104193A1 (en) 2011-05-05
EP2270172A1 (en) 2011-01-05
CA2838395C (en) 2016-07-19
NZ536676A (en) 2006-11-30
CY1117239T1 (el) 2017-04-05
BR0010721A (pt) 2002-06-11
CA2373236A1 (en) 2000-11-30
AU2006201153B2 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
ES2505695T3 (es) Composiciones inmunógenas para Streptococcus pyogenes
ATE410441T1 (de) Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidinanalogen
ATE333464T1 (de) Zusammensetzungen und verfahren zur behandlung von infektionen unter verwendung von kationischen peptiden allein oder in kombination mit antibiotika
DE60233532D1 (de) An proteinphosphatase 2a bindende synthetische ode anwendungen
DE69838143D1 (de) Antimikrobielle peptide
DK0690872T3 (da) Biologisk aktive peptider fra funktionelle domæner af baktericidt/permeabilitetsforøgende protein og anvendelser deraf
CO4940438A1 (es) Metodos mejorados para el procesamiento de proteina c acti- vada
ATE262348T1 (de) Mittel zur verabreichung von antigenen
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
DE59410380D1 (de) Endosomolytisch wirksame partikel
DE69401204D1 (de) Gonadotropin enthaltende gefriergetrocknete troepfen
DE50008510D1 (de) Niedermolekulare inhibitoren von komplementproteasen
ES2183170T3 (es) Composicion farmaceutica estable del factor bdnf.
DE60023860D1 (de) Verfahren zur herstellung von rekombinanten peptiden
EP1548107A4 (en) CHROMOPROTEIN AND FLUORO PROTEINS
ATE194777T1 (de) Mehrfachkomponenten-inklusionskomplexe enthaltend einen sauren arzneistoff, ein zyklodextrin und eine base
ATE439441T1 (de) Veränderte, fluoreszierende proteine
CO5570658A2 (es) Composicion y metodo para el tratamiento de la diabetes
CA2200069A1 (en) Anti-Fungal Peptides
ES2507094T3 (es) Proteína específica del timo
PT1276763E (pt) Proteinas anti-congelantes sua producao e utilizacao
DE60118935D1 (de) Dna & protein bindende miniatur proteine
PT1131408E (pt) Acidos oligossacarido-aldonicos e sua utilizacao topica
BR9809103A (pt) Forma farmacêutica estável de administração para peptìdeos, proteìnas e ácidos nucléicos
DK1219301T3 (da) Vacciner, som indeholder hybridpolypeptider, der består af mindst to forskellige allergene proteiner